Non Small Cell Lung Cancer
Conditions
Brief summary
This study compares paclitaxel/carboplatin (PC) to PC chemotherapy followed by gefitinib for 2 weeks in patients with Non-small Cell Lung Cancer (NSCLC) without epidermal growth factor receptor (EGFR) mutations. Expanded acronym : \[P\]aclitaxel/Ca\[r\]boplatin (PC) followed by Gef\[i\]tinib in A\[d\]vanc\[e\]d Non-small Cell Lung Cancer (NSCLC): Randomized phase II study.
Detailed description
A randomized phase II trial that compares paclitaxel/carboplatin (PC) to PC chemotherapy followed by gefitinib for 2 weeks in patients with NSCLC without EGFR mutations. While previous studies with cytotoxic agents and gefitinib failed to show any benefit, we altered the schedule of administration in hopes to gain synergy between agents.
Interventions
DRUGPaclitaxel/Carboplatin/Gefitinib
paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)/daily gefitinib 250mg/day during day 2-15
paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)
Sponsors
AstraZeneca
Asan Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* More than 18 years of age * Histologically documented non-small cell lung cancer with metastasis (Stage IV) or locally advanced (Stage IIIB) with malignant effusion. * At least 1 measurable lesion as defined by RECIST1.0. All target lesions must have a unidirectional diameter of at least 1cm. Baseline measurements must be compared within 4 weeks prior to enrollment. * ECOG PS 0-2 * At least 1 week since the last radiotherapy. Patients must have recovered from all acute toxicities from radiotherapy. * Patients must have adequate hematologic, renal and liver function as defined by Hb \> 9g/dL, neutrophils \> 1000/mm3, platelets \> 50,000/mm3, creatinine \< 2mg/dL, and AST (SGOT) and/or ALT (SGPT) \< 5 x UNL (upper normal limit). * Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures. * Written and voluntary informed consent understood, signed and dated.
Exclusion criteria
* Patients with tumor harboring EGFR mutation. * Prior systemic therapy for NSCLC * Non-smoking patients with adenocarcinoma. But if those patients show wild type EGFR, they are eligible to this study. * Symptomatic brain metastasis. Brain metastases stable \< 2 weeks before dosing or requiring concurrent steroid treatment or with clinical symptoms. * Major surgery within 3 weeks prior to study enrollment. * Previous (less than 3 years ago) or current malignancies at sites other than curatively treated in situ carcinoma of cervix, or basal or squamous cell carcinoma of the skin. * Severe medical illness or active infection that would impair the ability to receive gefitinib. * Pregnancy or breast feeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response Rate | average 6 months |
Secondary
| Measure | Time frame |
|---|---|
| progression free survival | average 2 years |
| overall survival | average 2 years |
Countries
South Korea
Outcome results
None listed